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Abstract General medical problems and complications
have a major impact on the quality of life in all stages of
Parkinson’s disease. To introduce an effective treatment, a
comprehensive analysis of the various clinical symptoms
must be undertaken. One must distinguish between (1)
diseases which arise independently of Parkinson’s disease,
and (2) diseases which are a direct or indirect consequence
of Parkinson’s disease. Medical comorbidity may induce
additional limitations to physical strength and coping
strategies, and may thus restrict the efficacy of the physical
therapy which is essential for treating hypokinetic-rigid
symptoms. In selecting the appropriate medication for the
treatment of any additional medical symptoms, which may
arise, its limitations, contraindications and interactions
with dopaminergic substances have to be taken into con-
sideration. General medical symptoms and organ mani-
festations may also arise as a direct consequence of the
autonomic dysfunction associated with Parkinson’s dis-
ease. As the disease progresses, additional non-parkinso-
nian symptoms can be of concern. Furthermore, the side
effects of Parkinson medications may necessitate the
involvement of other medical specialists. In this review, we
will discuss the various general medical aspects of
Parkinson’s disease.
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Introduction
The typical cardinal symptoms of Parkinson’s disease (PD)
are akinesia, rigidity, tremor and postural instability. The
long-term course of the disease becomes complicated by
motor and non-motor fluctuations and failing efficacy of
the medication (Storch et al. 2013). Specific assessments
and comprehensive tools are available for diagnostic and
therapeutic use (Chaudhuri et al. 2007; Marras and Lang
2008; Olanow et al. 2009; Rascol et al. 2011; Sprenger and
Poewe 2013). The influence of additional medical prob-
lems on the disease course, however, has so far only been
poorly described. The choice of an effective treatment for
the individual is determined by a precise differential-di-
agnostic classification of the various symptoms, because
these may have a direct impact on the severity of the
impairment and mortality (Parashos et al. 2002; Elbaz et al.
2003).
This report will focus on three major sub-groups: (1)
medical comorbidity, arising independently of the under-
lying disease, (2) clinical symptoms arising as a result of
disease-associated autonomic denervation, and (3) side
effects of the Parkinson’s disease medication itself, which
may necessitate the involvement of other specialists.
A limited number of review articles on comorbidity in
PD have been published, but none of these were entirely
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musculoskeletal comorbidities are statistically more likely
to internal diseases. Chronic medical diseases, such as
arterial hypertension or diabetes mellitus, despite their
sometimes severe impact, have only a slight influence on
overall morbidity (Leibson et al. 2006; Guttman et al.
2004; Gorell et al. 1994). This is surprising as many studies
have been published in which the relationship between PD
and individual diseases has been examined; however, these
studies did not consider the sometimes detrimental effect
the treatment of these additional symptoms can have on the
further course of PD.
The possible side effects associated with Parkinson
medication are numerous, and are described in detail in the
summaries of product characteristics (SPC) issued by
pharmaceutical companies for each product. Most of these
side effects, however, are infrequent and rarely lead to
discontinuation of the therapy. Cardiac valve pathology,
subsequent to the use of ergoline dopamine agonists, is one
of the serious side effects associated with the use of PD
medication, and this led to very stringent limitations on the
drug approval in 2007 and to the withdrawal of pergolide
for human use in the USA (Zanettini et al. 2007). Realizing
that a particular non-PD symptom may possibly be related
to a dopaminergic or anti-glutamatergic therapy is essential
for determining the correct course of treatment. Our report
will discuss the most important side effects which can lead
to either a change of or the cessation of medication.
The greatest cause of general medical problems in PD is
PD itself, mostly due to the functional disturbances that
arise from the autonomic denervation which affects nearly
all the organs (Goetz et al. 1986; Senarda et al. 1997;
Poewe 2008). For the present, the consequences of cardiac
and gastrointestinal denervation in particular, and the rea-
sons for involving specialists from other medical disci-
plines, will be addressed.
The reciprocal influence of general medical and neuro-
logical complications in PD requires a close and continu-
ous feedback between the neurologists and the other
medical specialists involved in the individual case. To date,
there is a dearth of prospective studies on this topic.
Some of the medical complications seen most frequently
in everyday clinical settings will now be examined in the
following sections.
General medical comorbidity
Patients with PD exhibit a high rate of multi-morbidity. In
various studies on comorbidity, up to 80 % of the patients
had five or more concomitant diseases (Gorell et al. 1994;
Leibson et al. 2006). The significance of this lies not only
in the higher degree of stress for the patient, but also in the
concomitant therapy of these medical diseases, as these can
seriously influence the overall treatment success or the rate
of mortality (Parashos et al. 2002; Elbaz et al. 2003; Doi
et al. 2011). Viewing the results of these studies, it is
apparent that, for at least the first years of PD, typical
medical diseases (such as diabetes mellitus) do not occur
more frequently among PD patients when compared to
control groups (Leibson et al. 2006). An increase in age-
correlated comorbidity cannot be found until after
10–15 years with PD and is clearly related to complica-
tions and sequelae of PD (Leibson et al. 2006). Most fre-
quent among these comorbidities are diseases of the joints
and fractures (Leibson et al. 2006; Melton et al. 2006;
Natalwala et al. 2009; Jones et al. 2012). In contrast, other
intercurrent diseases such as pneumonia or cardiovascular
disease are the principle cause of death in all mortality
studies (Gorell et al. 1994; Ben-Shlomo and Marmot 1995;
Pinter et al. 2014).
Diabetes mellitus
Although the data from several cohort studies revealed a
high level of comorbidity between PD and diabetes mel-
litus, these results have not been consistent (Cereda et al.
2011). A number of retrospective case studies have shown
a tendency for the co-occurrence of diabetes and PD, whilst
other studies failed to corroborate this finding (Gorell et al.
1994; Leibson et al. 2006; Hu et al. 2007; Becker et al.
2008; Jones et al. 2012). Other clinical studies reported an
increased risk of over 40 % for patients with diabetes to
develop PD (Miyake et al. 2010; Xu et al. 2011; Sun et al.
2012). In one population-correlated cohort study with an
observation period of 12 years, there was a 2.2-fold
increased risk for contracting PD, and this risk was in fact
raised by a further 57 % if the diabetics had been treated
with sulfonylurea (Wahlqvist et al. 2012).
The development of diabetes by PD patients is corre-
lated with increased cognitive deficits, gait disturbance and
postural instability (Bohnen et al. 2014; Kotagal et al.
2013). Recent genetic research has found an association
between both PD and diabetes mellitus and the SOD2*Val
polymorphism (Santiago et al. 2014).
The oral antidiabetic, metformin, has proven to be
effective in the therapy of diabetes mellitus, and now,
because of its neuroprotective and pro-dopaminergic
qualities, is attracting attention in animal models of PD and
in the treatment of PD patients. (Wang et al. 2012; Potts
and Lim 2012; Adeyemi et al. 2013; Patil et al. 2014;
Wahlqvist et al. 2012). The potential deficiency in vitamin
B12 which is linked to metformin use has been associated
with the occurrence of polyneuropathy (Bell 2010). As
polyneuropathy is a frequent neurological complication of
diabetes mellitus, and as vitamin B12 deficiency has also
been described in PD, screening for vitamin B12 deficiency
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is recommended for patients with diabetes and PD
(Ka¨stenbauer et al. 2004; Madenci et al. 2012; Ceravolo
et al. 2013). If diabetic nephropathy occurs as a result of
diabetes mellitus, dose adjustment has to be considered
when amantadine, budipine and pramipexole are being
prescribed (see http://www.dosing.de) (Horadam et al.
1981; Hong et al. 2008).
Dyslipidemia
The data on hypercholesterolemia and PD are inconsistent
(Hu et al. 2008; Miyake et al. 2010). One recent meta-
analysis failed to find an increased association between
elevated serum cholesterol and PD (Gudala et al. 2013).
HMG-CoA reductase inhibitors (statins) may arguably
have an anti-inflammatory, immune-modulating and neu-
roprotective effect (Gao et al. 2012; Undela et al. 2013). In
a meta-analysis, a relative reduction in risk of 29 % was
found for PD, but only for the group of patients under the
age of 60 (Gao et al. 2012). Nonetheless, the risk for car-
diovascular complications is increased for patients with PD
and hypercholesterolemia (Firoz et al. 2015).
Huang et al. prospectively examined plasma lipids and
statin use in relation to PD in the Atherosclerosis Risk in
Communities (ARIC) Study. Statin use and plasma lipids
were assessed at baseline and at three triennial visits
thereafter until 1998. Statin use may be associated with a
higher PD risk, whereas higher total cholesterol may be
associated with lower risk. These data are inconsistent with
the hypothesis that statins are protective against PD (Huang
et al. 2015).
Obesity
The relationship between obesity and PD is discussed very
controversially. Dopamine is involved in the regulation of
food intake. Obese persons have decreased dopamine D2
receptor availability in the striatum (Chen et al. 2004).
Based on this scientific knowledge, the relationship
between obesity and the risk of Parkinson’s disease was
several scientifically investigated. Chen et al. studied the
association between obesity and the risk of PD in two large
cohorts of US man and women from the ‘‘Health Profes-
sionals Follow-up Study’’ and the ‘‘Nurses’ Health Study’’.
The results do not support a role of overall obesity in PD
pathogenesis, however, central obesity may be associated
with higher PD risk among never smokers (Chen et al.
2004). Also in the Harvard Alumni Health Study, the body
mass index (BMI) was unrelated to Parkinson’s disease risk
(Logroscino et al. 2007). Hu et al. found in a Finnish cohort
that the risk of PD was twice as high in men with BMI over
30 and there was a 70 % higher risk among women (Hu
et al. 2006).
Previous studies have also suggested an association
between PD and obesity as comorbidity. In a cross-sec-
tional study in the PD group 19.2 % were obese (Morales-
Bricen˜o et al. 2012). In a Mexican general population, the
prevalence for overweight was 20.3 % (OR 1.45,
p \ 0.0001, CI 95 % 1.65–2.12), compared to general
population (Llorens-Arenas et al. 2015).
Arterial hypertension
The role of arterial hypertension as a risk factor for the
development of PD has been examined in a number of
case–control and retrospective studies, showing that the
risk for developing PD was rather lower for hypertensive
patients than for those with normotension (Miyake et al.
2010; Qiu et al. 2011; Mazza et al. 2013). Cardiac den-
ervation in PD complicates the therapy for arterial
hypertension through some special features of blood
pressure in PD patients. Reducing blood pressure with
medication in a supine patient increases the risk of a
symptomatic OH. To avoid this, prescribing short-acting
antihypertensives can be recommended for the time
between meals, for the later afternoon or in the evening
(Mazza et al. 2013). Some of the antihypertensives (such
as calcium antagonists and ACE inhibitors) are attributed
with a neuroprotective effect towards the development of
PD (Rodnitzky 1999; Ritz et al. 2010; Mazza et al. 2013;
Sato et al. 2014), something which, however, could not be
confirmed in individual studies or in a Cochrane analysis
in 2011 (Simon et al. 2010; Rees et al. 2011a; Marras
et al. 2012). The calcium antagonist isradipine is an
exception (Simuni et al. 2010; Ilijic et al. 2011; Kang
et al. 2012; Simuni et al. 2013). A Phase II study is
currently being conducted by the Parkinson Study Group
into the drug safety and compatibility of isradipine in the
modification of PD in early stages of the disease (Simuni
et al. 2010). A retrospective case analysis of 341 PD
patients has found interesting results, showing that co-
medication with beta blockers was associated with a
weaker risk of developing PD (42.4 versus 65.6 % with-
out beta blockers in the concomitant medication) (Pagano
et al. 2014).
In selecting the appropriate antihypertensives, active
substances which, based on their pharmacological proper-
ties, can cause drug-induced parkinsonism, should be
avoided. Studies on this relationship have been done for
alpha-methyldopa (Strang 1966; Vaidya et al. 1970;
Rosenblum and Montgomery 1980), reserpine (Birkmayer
and Hornykiewicz 1964; Lorenc-Koci et al. 1995), calcium
channel blockers (flunarizine, cinnarizine, amlodipine)
(Montastruc et al. 1994; Sempere et al.1995; Teive 2002),
diltiazem (Dick and Barold 1989; Graham and Stewart-
Wynne 1994; Remblier et al. 2001), verapamil (Malaterre
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et al. 1992; Padrell et al. 1995), captopril (Sandyk 1985)
and moxonidine (Webster and Koch 1996).
Obstructive sleep apnea syndrome (OSAS)
Patients with PD can develop obstructive sleep apnea
syndrome (OSAS). OSAS causes daytime sleepiness,
nocturnal high blood pressure, and glucose intolerance.
There is no conclusive evidence to support the association
between PD and the prevalence of OSA. A meta-analysis
evaluates five eligible studies including 322 cases and 6361
controls. The results suggest that there is a significant
negative association between PD and the prevalence of
OSA. Patients with PD generally have a reduced preva-
lence of OSA (Zeng et al. 2013). In cases of PD with
moderate or severe OSAS, the use of continuous positive
airway pressure (CPAP) is established in treatment. The
patients responded to therapy and regained more daytime
activity. Therefore, sleep diagnostic evaluation is recom-
mended to rule out sleep apnea as a cause for hypersom-
nolence (Steffen et al. 2008).
Cardiomyopathy
Comorbidity between cardiomyopathy and PD is signifi-
cantly raised compared to controls and reaches 19.4 %
(Zesiewicz et al. 2004). One possible cause of this—the
basic deficit of sympathetic innervation in PD—is still
under discussion (Satoh et al. 1999). The postsynaptic
noradrenaline uptake in sympathetic nerve endings of the
heart, as measured with MIBG-SPECT (123-I-Meta-
Iodobenzylguanidine), serves as a marker for this disorder
of innervation (Satoh et al. 1999). Studies using nuclear
imaging, however, failed to confirm an association
between orthostatic dysregulation (the clinical correlate of
an autonomous functional disorder) and the cardiovascu-
lar disorder, so that it is now being postulated that their
development is fully independent of one another (Haensch
et al. 2009; Leite et al. 2014). Studies undertaken in an
animal model found only a weak effect of cardiomyopa-
thy on the progression of PD (Xu et al. 2014). Similarly,
no significant negative effect of Levodopa therapy on
cardiac disease could be documented (Jenkins et al.
1972).
When diuretics are called for to treat cardiac insuffi-
ciency, a combination of amantadine and dyazide (hy-
drochlorothiazide, triamterene) should be avoided. Dyazide
reduces the clearance of amantadine, and thus toxic plasma
levels are possible (Wilson and Rajput 1983). Single case
reports have described akinesia, tremor, drug-induced
parkinsonism and severe gait ataxia arising from the use of
the anti-arrhythmic amiodarone (Lombard et al. 1986;
Werner and Olanow 1989; Dotti and Federico 1995;
Malaterre et al. 1997; Krauser et al. 2005; Ishida et al.
2010). The causative factor was attributed to amiodarone-
induced dysfunction of the basal ganglia (Werner and
Olanow 1989). A postmortem case report described the
toxic accumulation of amiodarone in the basal ganglia
(Ishida et al. 2010). The cumulative incidence of a possibly
neurotoxic effect of amiodarone (tremor, gait ataxia,
peripheral neuropathy, cognitive deficits) was found to be
2.8 % in a retrospective case analysis (Orr and Ahlskog
2009).
Gastritis and gastroesophageal reflux
The prevalence of gastroesophageal reflux disease (GERD)
is high in PD, and reaches 65 % in patients 4 years after
diagnosis (Makaroff et al. 2011; Maeda et al. 2013).
Therapy is conducted with proton pump inhibitors (PPI).
Single case studies have documented a dose-dependent
increase in the incidence of vitamin B12 deficiency, frac-
tures and infections with clostridia in at-risk patients,
although it must be admitted that randomized controlled
studies are as yet lacking (Hirschowitz et al. 2008; Roz-
gony et al. 2010; Heidelbaugh 2013). Usage of PPI in strict
dosage is recommended and should be adhered to these
patients with GERD (Abraham 2012; Leibson et al. 2006;
Madenci et al. 2012).
Helicobacter pylori infection
The prevalence of helicobacter pylori (HP) infection in PD
patients is high and ranges from 37 to 59 % in different
publications (Rees et al. 2011b). In several case–control
studies, a negative influence has been reported for HP
infection of the stomach lining on the absorption of levo-
dopa and subsequent motor behavior in patients with PD
(Tan et al. 2014b). According to some authors (Pierantozzi
et al. 2006; Lee et al. 2008), eradication improves the effect
of the levodopa and leads to a reduction in the rate of
fluctuations. A review article from the Cochrane Collabo-
ration, however, found but few indications for an
improvement in motor behavior, so that screening of PD
patients for HP cannot be recommended at present (Rees
et al. 2011b). As a result of untreated and chronic gastritis
due to HP infection, an iron deficiency anemia can occur
which disappears spontaneously after successful eradica-
tion. One study involving 22 patients, however, found no
difference between eradication with and without iron sub-
stitution (DuBois and Kearney 2005). If iron substitution is
considered necessary in Parkinson’s patients, an interval of
at least 2 h should be observed between the use of the iron
preparation and levodopa/DDCI or a COMT inhibitor, as
otherwise chelation can occur (Orama et al. 1997; Kaak-
kola 2000).
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Small intestinal bacterial overgrowth syndrome
(SIBO)
Several studies have reported finding an increase in the
prevalence of small intestinal bacterial overgrowth syn-
drome (SIBO) in PD (Gasbarrini et al. 2007; Gabrielli et al.
2011). A possible association of SIBO presenting with
gastrointestinal symptoms and a worsening of motor
behavior is being considered at present (Gasbarrini et al.
2007; Fasano et al. 2013; Tan et al. 2014a). In a study
involving 33 patients and 30 controls, 54.5 % of PD
patients and only 20 % of controls (p = 0.01) had SIBO.
The affected PD patients had longer off-phases and more
frequent delayed-on and no-on episodes (Fasano et al.
2013). Gastrointestinal hypomotility in PD with delayed
peristalsis and a disorder in the functioning of the Valva
ileocaecalis are under consideration as the possible causal
factor (Gabrielli et al. 2011). Under standard study
requirements, melevodopa (levodopa methyl ester) proved
to be more effective than levodopa in patients with PD and
SIBO due to changes in the pharmacological dynamics
(Fasano et al. 2014).
Leaky gut syndrome (LGS)
Recent studies suggest that leaky gut syndrome, in asso-
ciation with an abnormally heightened intestinal perme-
ability (gut leakiness) for enterobacteria and exogenic
toxins from the intestinal lumen, is more frequent in PD. In
view of the studies by Braak et al. (2003), the relationship
between the subsequent changes in the intestine and the
pathophysiology of PD has attracted substantially more
attention (Forsyth et al. 2011; Scheperjans et al. 2014).
LGS is presently being investigated extensively in
numerous study projects [Increased Gut Permeability to
Lipopolysaccharides (LPS) in Parkinson’s Disease,
NCT01155492, Quantitative Analysis of Gut-derived
Neuropeptides in Cerebrospinal Fluid (CSF) of Patients
With Parkinson’s Disease and Healthy Controls,
NCT01792193, etc.].
Clinical disorders arising as side effects
of Parkinson’s disease medication
Fibrosis and fibrotic cardiac valve damage
As early as the early 1990s, individual case reports
described fibrotic changes in various organs such as pleu-
ral, pericardial and retroperitoneal fibroses in patients
receiving the ergoline dopamine agonists bromocriptine,
pergolide and cabergoline (Jime´nez-Jime´nez et al. 1995;
Lund et al. 1999; Shaunak et al. 1999; Mondal and Suri
2000; Bilici et al. 2004; Apostolakis et al. 2009; Elenkova
et al. 2012). In addition, since 2007, numerous observa-
tional studies have shown a relationship between the
ergoline dopamine agonists pergolide and cabergoline and
the occurrence of fibrotic cardiac valve damage (Antonini
and Poewe 2007; Zanettini et al. 2007; Schade et al. 2007;
Steiger et al. 2009). Pathophysiologically, it has been
proposed that activation of the 5-hydroxytryptamine 2B
receptors (5HT2B) located on the cardiac valves stimulates
the growth of fibroblasts in the endocardium (Setola et al.
2003; Horowski et al. 2004). This hypothesis was con-
firmed in a large cohort study involving 11,417 partici-
pants. An increased incidence of fibrosis (dose dependent,
over 3 mg/day) was found with pergolide (sevenfold
increase) and cabergoline (fivefold increase), and both
substances had a strong 5-HT2B affinity. No association
could be found for ropinirole, pramipexole or rotigotine
(Andersohn and Garbe 2009). According to a publication
of the FDA, pergolide was then withdrawn from the market
by the manufacturers (FDA 2007) while drug approval for
pergolide and cabergoline was maintained in Europe and
Japan but subject to the following restrictions: both dopa-
mine agonists are considered as drugs of second choice and
the maximum daily dose for both preparations is set at
3 mg. If therapy should call for one of these medications,
close monitoring of echocardiographical and medical
parameters is mandatory. A prior fibrotic condition or
cardiac valve stenosis is a contraindication (EMA 2008).
Cardiac insufficiency
In 2012, the FDA announced for the first time that there
was a possible association between pramipexole and the
risk of cardiac insufficiency. Such indications had arisen in
an evaluation of the side effects documented in the
pramipexole approval studies from 2010 (FDA 2012). An
epidemiological study performed by the manufacturer
revealed an increased risk of cardiac insufficiency for
pramipexole (RR 1.86) and for cabergoline (RR 2.07)
(Renoux et al. 2012). In a second large cohort study, uti-
lizing the results obtained from the United Kingdom
General Practice Research Database (GPDR), the use of
pramipexole was associated with a greater risk for cardiac
insufficiency (odds ratio 1.61). This increase in risk was
especially apparent in the first 3 months of treatment and in
patients aged 80 years or over (Mokhles et al. 2012). A
meta-analysis in 2014 confirmed this increased risk for
pramipexole and cabergoline (Perez-Lloret et al. 2014). To
date, there have been no therapy limitations or health
warnings for pramipexole due to insufficient data. Use of
cabergoline has been severely limited at any rate, because
of the risk of developing fibrosis. Further studies were
called for by the FDA.
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Single case studies have reported the occurrence of
cardiac insufficiency under amantadine (Vale and Maclean
1977; Parkers et al. 1977).
Peripheral edemas
The occurrence of peripheral edemas, most notably in the
ankles and the lower legs, has been associated with dopa-
mine agonists and amantadine, with the frequency ranging
between 5 and 40 %. In a retrospective analysis from the
CALM-PD Study, risk factors for the occurrence of
peripheral edemas under pramipexole were found for
female gender and cardiac comorbidity (Biglan et al.
2007). A single case of massive lymph edema associated
with pramipexole treatment, which resolved following
cessation of the drug, has been reported (Zavala et al.
2012). In one long-term study on ropinirole extended
release, 38.6 % of the patients developed peripheral ede-
mas (Hauser et al. 2011). A lower degree of risk was found
in studies on rotigotin (7 %) and piribedil (5 %) (Giladi
et al. 2013; Castro-Caldas et al. 2006). Edemas under
amantadine were associated with peripheral vasoconstric-
tion (Pearce et al. 1974).
In individual cases, amantadine has been associated with
the following diseases: Livedo reticularis, SIADH (syn-
drome of inappropriate antidiuretic hormone secretion),
hyponatremia and cornea edemas (Pearce et al. 1974;
Blanchard 1990; Fraunfelder and Meyer 1990; Lammers
and Roos 1993; Gibbs et al. 2005; Alonso Navarro et al.
2009; Trenkwalder et al. 2007; Kim et al. 2013).
Arrhythmia due to long QT syndrome
Some Parkinson’s medications may induce prolongation of
the QT interval and as a result increase the risk of
arrhythmia of the Torsades de Pointes (TdP) type. For this
reason, very close supervision is called for when admin-
istering budipine (Scholz et al. 2003). When two drugs
with a potential for QT prolongation are administered in
combination, the risk is increased by 70 % and for this very
reason is contraindicated (Heist and Ruskin 2005). Even
amantadine can lead to a QT prolongation (Manini et al.
2007). Drugs with this risk for QT prolongation when
frequently administered in Parkinson’s patients also
include apomorphine, domperidone, citalopram and esci-
talopram. For a review of other drugs, see http://torsades.
org/medical-pros/drug-lists/drug-lists.htm.
Diarrhea
Diarrhea is a frequent or very frequent non-dopaminergic
side effect when patients are treated with COMT inhibitors
(Parashos et al. 2004; Kaakkola 2010), persisting even after
patients are taken off the drug. Case reports have described
the occurrence of colitis under entacapone and Stalevo
(levodopa/carbidopa/entacapone) (Maroy 2008; Lim et al.
2008). Pathological liver test results are a contraindication
for COMT inhibitor therapy.
COMT inhibitors harbor the potential for liver toxicity,
and in the case of tolcapone but not of entacapone, this
constitutes a safety risk (Haasio et al. 2002). Following the
market authorization for tolcapone in 1997, three patients
died from acute liver failure, which led to the withdrawal
of the drug from the European market. However, further
safety evaluations led to its re-approval in 2004 (Borges
2003; Brooks 2004). Tolcapone is now considered as a
COMT inhibitor of second choice in treating advanced
Parkinson’s disease when fluctuations are present, but
nonetheless regular liver enzyme monitoring is mandated.
In rare cases even the dopa decarboxylase inhibitor
benserazide (contained in levodopa/benserazide formula-
tions) can cause diarrhea (Csoti and Fornadi 2011).
Changing to levodopa/carbidopa is in most cases benefi-
cial. The risk of diarrhea is especially apparent with single
doses of benserazide of over 25 mg (as in Madopar
250 mg). Because tolcapone, due to drug interactions, can
in turn raise the benserazide levels, a combination of
200/50 mg levodopa/benserazide formulations with tol-
capone should be avoided (summary of product charac-
teristics for Tasmar 100 mg 2013).
Pathological glucose tolerance and insulin resistance
under L-Dopa
Dopamine influences insulin secretion. There are descrip-
tions in the literature of a tonic inhibition of glucose-con-
trolled insulin secretion from the b-cells of the pancreas
(Ustione et al. 2013). Sirtori et al. (1972) investigated the
metabolic effect of Levodopa in 24 patients and found
pathological glucose tolerance after a treatment time of
1 year and an increase in serum cholesterol of approxi-
mately 10 %. Insulin resistance has also been described as
being significantly higher among Parkinson’s patients with
dementia (Bosco et al. 2012).
Symptoms of autonomic dysfunction
Cardiovascular autonomic disorders
Syncopes in orthostatic hypotension
The most common autonomic disorder within the cardio-
vascular system in PD is orthostatic hypotension (OH),
which in the literature is reported to affect 30–60 % of
patients (Bellon et al. 1996; Senarda et al. 1997). The
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assumption that this disorder does not appear until the
advanced stages of PD has been disproven in more recent
studies (Jost and Augustis 2015). These patients typically
have a sudden drop in blood pressure below the critical
limit for cerebral autoregulation after a change of position,
postprandially or in the recovery phase after physical strain
(Jost 1995; Loew et al. 1995; Mehagnoul-Schipper et al.
2001; Ejaz et al. 2006; Ziemssen et al. 2006). Assumed
causal factors include: (1) cardiac noradrenergic denerva-
tion as demonstrated in MIBG-SPECT (meta-iodobenzyl-
guanidine), (2) extra-cardiac noradrenergic dysfunction
and (3) a disturbance of the cardiovagal and sympa-
thoneural reflex (Kaufmann and Goldstein 2013; Rahman
and Goldstein 2014). In addition to cardiac denervation,
OH can be increased by dehydration or medication (Jacob
et al. 1997). OH as a side effect of Parkinson’s disease
medication has been particularly described in association
with dopamine agonists and selegiline, but is also possible,
according to the summary of medicinal product charac-
teristics (SMPC), with L-Dopa, COMT inhibitors and
amantadine (Sachs et al. 1985; Mesec et al. 1993; Kujawa
et al. 2000; Pursiainen et al. 2007). If additional medication
is required because of non-motor symptoms of the disease
or concurrent diseases, a worsening of OH is possible with
antihypertensives/diuretics, atypical neuroleptics (clozap-
ine, quetiapine), alpha-receptor blockers for treatment of
benign prostatic hyperplasia, antidepressants (in particular
tricyclic antidepressants) and opioids (SMPC). Clinical
symptoms include dizziness, drowsiness, nausea, and
presyncopal or syncopal events. Typically, a painful feel-
ing of pressure in the occipital region or the area of the
neck–shoulder, the so-called ‘‘coat hanger sign’’ is descri-
bed (Bleasdale-Barr and Mathias 1998). Therapy should
initially consist of modifying both the Parkinson’s and
other medication and increasing liquid intake (Young and
Mathias 2004; Connolly and Lang 2014). If other medi-
cations are being considered, favorable results have been
obtained for domperidone, fludrocortisone, midodrine,
droxidopa, pyridostigmine and fipamezole (Seppi et al.
2011; Perez-Lloret et al. 2014; Biaggioni 2014; Isaacson
and Skettini 2014).
Nocturnal high blood pressure (non-dipping)
In addition to OH, 50–90 % of Parkinson’s patients have
an increase in blood pressure when in a supine position
and, as a consequence, at night (Schmidt et al. 2009;
Sommer et al. 2011; Oh et al. 2013). The occurrence of this
autonomous circulatory dysregulation is not necessarily
associated with OH. Such a disturbed circadian blood
pressure regulation is called non-dipping and can be so
pronounced that nocturnal antihypertensive medication
becomes necessary (Sommer et al. 2011). In order not to
aggravate the early morning OH after rising, antihyper-
tensives should be selected with short duration of action
(Mazza et al. 2013). If the increase in nocturnal blood
pressure is not recognized and treated, this becomes a
major risk factor for developing left ventricular hypertro-
phy and an associated increased risk for cerebrovascular
events (Koroboki et al. 2015).
Changes in heart rate frequency
Heart rate variability (HRV, previously termed respiratory
sinus arrhythmia) designates physiological variations in
heart beat intervals which range within the frequency of
respiration. HRV is considered a parameter of autonomous
cardiac innervation and is frequently attenuated in
Parkinson’s patients (Malik 1996; Haapaniemi et al. 2001).
This in turn is associated with a higher rate of cardiovas-
cular morbidity and mortality, and not only in cases of
diabetes mellitus, but also in PD (Feil et al. 1994; Lo¨llgen
1999; Chen et al. 2011). The studies published to date have
failed to find a correlation between an attenuated HRV and
the severity of PD, so that attenuated HRV is classified
with the early autonomous disorders in PD (Harnod et al.
2014; Haensch et al. 2009; Maetzler et al. 2014).
Autonomic nervous system disorders in the gastrointestinal
tract
Autonomous disorders can occur in the whole of the gas-
trointestinal tract. The resultant clinical symptoms vary
though because of overlap with primary motor symptoms
such as akinesia and rigidity (Pfeiffer 2011). The concur-
rent gastrointestinal diseases that result from these auton-
omous disorders lead to a highly significant reduction in
compliance in taking the Parkinson’s disease medication
regularly and also to a significant degree of malnutrition
with its own particularly impact (Richy et al. 2013; Sheard
et al. 2013). Thus, an inverse correlation was found
between PD and vitamin D deficiency, while an association
with the disease-caused gastrointestinal dysfunction could
not be excluded (Wang et al. 2014).
Pathological alpha-synuclein aggregates in the enteric
gastrointestinal tract, the dorsal vagus nucleus and brain
stem have been identified as causal factors for the occur-
rence of this autonomous dysfunction (Cerso´simo and
Benarroch 2012).
Hypersalivation/sialorrhea
A recent prevalence study involving 518 Parkinson patients
reported a 52.7 % incidence of hypersalivation (Ou et al.
2014). The cause for such hypersalivation is a reduction in
swallowing frequency in combination with dysphagia (Kalf
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et al. 2009; Srivanitchapoom et al. 2014), while saliva
production itself is in fact reduced (Cerso´simo et al. 2009).
Use of anticholinergic medication for treating hypersali-
vation is limited by the high potential for side effects
(Katzenschlager et al. 2003). Positive study results are
available for botulinum toxin and glycopyrrolate (Evidence
Level A) (Seppi et al. 2011; Go´mez-Caravaca et al. 2014,
Jost 2015). The topical substances ipratropiumbromide,
scopolamine and tropicamide as well as oral clonidine are
classified as probably effective (evidence level B), but all
these preparations have side effects. The use of radiother-
apy on the salivary glands is presently being examined
(Lakraj and Moghimi 2013; Go´mez-Caravaca et al. 2014).
It is difficult to treat dysphagia and in advanced stages
of PD it is often coupled with the risk of aspiration and
aspiration pneumonia (Troche et al. 2014). Disturbed
oropharyngeal phase of swallowing and a pharyngeal and
esophageal dysfunction (already present in early phases of
PD) with delayed or inverse bolus transport, stasis or ter-
tiary contractions have all been identified as causes of
aspiration (Leopold and Kagel 1997; Sung et al. 2010). PD
is therefore classified as a risk factor for developing sec-
ondary gastroesophageal reflux disease (GERD). It can
manifest as erosive reflux disease, erosive esophagitis,
Barrett esophagus and extra-esophageal (Koop et al. 2005),
which was confirmed by an epidemiological study on the
prevalence of gastrointestinal diseases in PD (Makaroff
et al. 2011).
Gastroparesis
As described above, delayed gastric emptying has a mul-
tifactorial genesis (Marrinan et al. 2014), and manifests in
symptoms such as abdominal fullness, nausea, acid indi-
gestion, lack of appetite and even vomiting (Edwards et al.
1993) and leads also to a reduction in L-dopa absorption.
Closely associated with these symptoms is a delayed or no
effect of onset of the dopaminergic agents with a con-
comitant deterioration in motor symptoms (Del Tredici and
Jost 2012). Domperidone has, until now, been regarded as
the gold standard for treating gastrointestinal symptoms in
PD, but because of its possible cardiotoxicity (long QT
syndrome) there are concerns about its safety (Lertxundi
et al. 2013). According to the recommendations of the
EMA, domperidone should be used in the lowest possible
dosage for as short a duration as possible and the maximum
duration of treatment should usually not exceed 1 week
(EMA 2014). Recent studies examining the role of ghrelin
in treating delayed gastric emptying and its possible neu-
roprotective effect in PD are of interesting regarding this
topic (Karasawa et al. 2014; Bayliss and Andrews 2013).
Several additional studies are currently evaluating the
efficacy of a minimally invasive, laparoscopically
implanted neurostimulator for treating gastroparesis (Ross
et al. 2014). When gastroparesis induces a significant
limitation on the clinical effectiveness of orally adminis-
tered Parkinson medication, transdermal, subcutaneous or
percutaneous-intestinal formulations are available (Giladi
et al. 2010; Martinez-Martin et al. 2014).
Constipation
Constipation, a dysfunction of the colon, is among the most
frequent autonomic disorders described in PD and inter-
estingly, may precede motor symptoms by a good many
years (Martignoni et al. 1995; Rossi et al. 2014). In addi-
tion, an observational study found that constipation
increased the risk of contracting PD by a factor of 4.5
(Abbott et al. 2001). Defecographic studies have shown a
prolonged colon transit time, a reduction in rectal phasic
contractions, abdominal muscle weakness and evidence of
paradoxical sphincter contraction during defecation
(Sakakibara et al. 2003). In addition to the basic autono-
mous disorder, obstipation can be worsened by exogenous
factors such as lack of movement, dehydration, poor diet-
ary choices, or anticholinergic medications (Rossi et al.
2014). Case studies have also documented the following
complications of constipation: megacolon, pseudo-ob-
structions or even volvulus, ileus or intestinal perforation
(Kupsky et al. 1987; Rosenthal and Marshall 1987; Mar-
inella 1997; Tateno et al. 2011a).
A significant positive effect was found for L-dopa on
disorders of anorectal function, with a resultant improve-
ment in constipation (Tateno et al. 2011b). Macrogol
(polyethylene glycol), lubiprostone and serotonin agonists
have also been shown to be efficacious in the treatment of
constipation in PD (Zangaglia et al. 2007; Del Tredici and
Jost 2012; Nurko and Saps 2014; Rossi et al. 2014). The
use of probiotics by PD patients was shown to be associ-
ated with an improvement in stool consistency and the
frequency of bowel evacuation (Cassani et al. 2011). In
addition to non-pharmacological treatment (for example
pelvic floor exercise, biofeedback), L-Dopa, apomorphine
injections and botulinum toxin-A injections into the pub-
orectalis muscle have proven useful in rare cases of rectal
dysfunction due to abdominopelvic dyssynergy (Rossi
et al. 2014). Dietary measures and the cessation of anti-
cholinergic drugs should precede any additional drug or
invasive therapy.
Summary
Parkinson’s disease is a chronic and progressive neurode-
generative disorder in which the motor disturbances and
emotional and cognitive deficits are the most prominent
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features. Present day treatments such as combined
L-dopa/dopamine agonist therapy administered either
orally, subcutaneously or transdermally, and neurosurgical
interventions which target these symptoms have proven to
be of some success, yet these symptoms are not the only
symptoms of concern. In the long-term course of the dis-
ease, therapy becomes increasingly complicated, in par-
ticular because of symptoms which arise as a result of the
non-dopaminergic side effects of Parkinson’s medication,
concomitant diseases acquired with aging and the large
number of additional autonomic disorders.
The gastrointestinal symptoms associated with Parkin-
son’s disease are a good example of the further medical
complications which patients may develop. Helicobacter
pylori infections in the stomach, abnormal bacterial colo-
nization of the small intestine and constipation are not only
under consideration as potential risk factors for the devel-
opment of PD, but also may arise as a consequence of PD,
due to its detrimental consequences on gastrointestinal
motility. Malabsorption may occur subsequent to bacterial
contamination of the small intestine, leading to deficiency
of vitamin B12, for example. Such deficiencies are more
frequent in patients with PD and lead to a deterioration in
the rate of morbidity and mortality (Gasbarrini et al. 2007;
Orr and Ahlskog 2009; Tan et al. 2014a, b).
Treatment safety for our patients depends vitally on the
careful observation of undesired side effects of medication,
and precisely monitoring, systematically evaluating and
designing therapy recommendations. This basic principle
has of course been implemented in the recent past in drug
therapy for Parkinson’s and has consequently led to
restrictions on approval and market withdrawals, and also
to re-approvals with improved compulsory requirements.
Only with further randomized and controlled studies
involving a sufficiently high number of participants, will
severe side effects be reduced or completely avoided.
The large extent of autonomic disorders in the entire
sympathetic and parasympathetic nervous systems and the
concomitant associated large variety of clinical symptoms
necessitate a detailed knowledge of this neurological dis-
ease with its associated additional medical consequences.
Adequate long-term therapy is only possible through the
close cooperation of the different specialists involved.
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